Physician profile
Rosemary E Hansen
NPI 1548534001
$40,212.36
in general payments reported to CMS, 2019-2025
23 companies · $23K in 2025
The $23K reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,974 · 2022: $2,782 · 2023: $4,877 · 2024: $2,472 · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $13K · Food and Beverage: $8,249 · Consulting Fee: $7,750 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $12,657.68 |
| Food and Beverage | $8,248.80 |
| Consulting Fee | $7,750.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $32,852.69 | 2021-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Pascal |
| Boston Scientific Corporation | $2,432.00 | 2021-2025 | Watchman, Watchman Flx, Watchman Access System |
| Medtronic, INC. | $1,386.12 | 2021-2025 | Corevalve Evolut R, Symplicity G3 |
| Abbott Laboratories | $783.41 | 2021-2025 | Navitor, Amplatzer Amulet, Triclip |
| Aop Health US, LLC | $589.97 | 2025 | Rapiblyk |
| Abiomed | $324.42 | 2021-2022 | |
| Pfizer INC. | $319.39 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $239.01 | 2022-2025 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $234.31 | 2021-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $183.16 | 2021-2022 | |
| Cvrx, INC. | $144.73 | 2024 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $137.38 | 2021-2023 | Uptravi |
| Siemens Medical Solutions USA, INC. | $134.06 | 2023 | Artis Icono Floor |
| Janssen Pharmaceuticals, INC | $100.15 | 2021-2024 | Xarelto |
| Kestra Medical Technology Services, INC. | $64.87 | 2022-2025 | Assure Wcd |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.78 | 2021-2024 | Jardiance |
| Alnylam Pharmaceuticals INC. | $56.45 | 2024-2025 | Onpattro |
| Merck Sharp & Dohme LLC | $48.66 | 2025 | Winrevair |
| Lexicon Pharmaceuticals, INC. | $35.18 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.89 | 2023 | Aralast |
| United Therapeutics Corporation | $24.71 | 2022 | |
| Terumo Medical Corporation | $18.31 | 2025 | Metacross Otw, Glidewire, Heartrail |
| Baxter Healthcare | $16.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosemary Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.